Rapid control of chronic granulocytic leukaemia.
Sixty patients with chronic granulocytic leukaemia (CGL), anaemia, hyperleucocytosis and hepatosplenomegaly were randomized into 3 treatment schedule consisting of: (i) cyclophosphamide 600 mg/m2 intravenously (i.v.) on day 1. (ii) cytosine arabinoside 100 mg/m2 subcutaneously (sc) 12 hourly for days 1-5. (iii) combination of i.v. cyclophosphamide 600 mg/m2 one day 1 and cytosine arabinoside 100 mg/m2 12 hourly sc for days 1-5. Each cycle of treatment lasted 7 days. Patients on combined chemotherapy achieved laboratory and clinical remission within 28 days of treatment, while patients on single agent chemotherapy of cytosine arabinoside or cyclophosphamide still had hyperleucocytosis and hepatosplenomegaly after 28 days of treatment. Six patients treated with cyclophosphamide only had thrombocytopenic bleeding, but no patient treated with either cytosine arabinoside only or a combination of cytosine arabinoside and cyclophosphamide bled. It is suggested that patients with CGL, anaemia, hyperleucocytosis, and hepatosplenomegaly can be rapidly controlled with a combination of cytosine arabinoside and cyclophosphamide.
Onwukeme
K E
KE
Department of Pathology/Haematology, Faculty of Medical Sciences, University of Jos, Nigeria.
Lot
T Y
TY
D000328:Adult; D000740:Anemia / Q000097:blood / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002985:Clinical Protocols; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006529:Hepatomegaly; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007964:Leukocytosis / Q000097:blood / Q000209:etiology; D008297:Male; D012074:Remission Induction; D013163:Splenomegaly; D013997:Time Factors
D003561:Cytarabine; D003520:Cyclophosphamide